Table I.
Baseline characteristics of patients in the trials included in the meta-analysis.
| Authors, year | Clinical trial | Type of study | Treatment regimen | Subgroup analysis | Refs. |
|---|---|---|---|---|---|
| Maughan et al, 2011 | COIN | Phase III | Oxa+FU vs. Oxa+FU+cet | KRAS BRAF | (4) |
| Bokemeyer et al, 2011 | OPUS | Phase II | FOLFOX-4+cet vs. FOLFOX-4 | ITT KRAS BRAF | (3) |
| Van Cutsem et al, 2011 | CRYSTAL | Phase III | FOLFIRI vs. FOLFIRI+cet | ITT KRAS BRAF | (2) |
| Tveita et al, 2012 | NORDIC-VII | Phase III | A; Nordic FLOX B: FLOX+cet C: intermittent FLOX +cet | ITT KRAS | (5) |
| Stintzing et al, 2012 | AIO-0306 | Phase III | FOLFIRI+cet vs. FOLFIRI +bev | ITTb | (17) |
| Ye et al, 2013 | Phase III | CT+cet vs. CT | ITTc | (19) | |
| Heinemann et al, 2014 | FIRE-3 | Phase III | FOLFIRI +cet vs. FOLFORI +bev | ITTc KRAS RAS | (18) |
| Van Cutsem et al, 2015 | CRYSTAL | Phase III | FOLFIRI vs. FOLFIRI+cet | KRAS RAS | (16) |
| Bokemeyer et al, 2015 | OPUS | Phase II | FOLFOX-4+cet vs. FOLFOX-4 | KRAS RAS | (20) |
a
Tveit 1: arms B vs. A; Tveit 2: arms C vs. arms A.
b
Among the whole population with data available on KRAS-mt status.
c
Among the whole population with data available about KRAS-wt status. cet, cetuximab; bev; bevacizumab; Oxa + FU, oxaliplatin + fluoropyrimidine; FOLFOX-4, 5-fluoropyrimidine + folinic acid + oxaliplatin; FOLFIRI, fluorouracil + leucovorin + irinotecan; Nordic FLOX, fluorouracil/folinic acid and oxaliplatin; FLOX, oxaliplatin + fluoropyrimidine; CT, FOLFIRI (fluorouracil + leucovorin + irinotecan) or mFOLFOX6 (modified fluorouracil + leucovorin + oxaliplatin); ITT, intention-to-treat.